Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands
Abstract Background The most important goal for survival benefit of advanced stage ovarian cancer is to surgically remove all visible tumour, because complete cytoreductive surgery (CCS) has been shown to be associated with prolonged survival. In a remarkable number of women, CCS is very challenging...
Main Authors: | G. M. Nieuwenhuyzen-de Boer, W. Hofhuis, N. Reesink-Peters, P. C. Ewing-Graham, I. G. Schoots, J. J. Beltman, J. M. J. Piek, A. Baalbergen, G. S. Kooi, A. van Haaften, H. van Huisseling, L. Haans, M. Dorman, H. J. van Beekhuizen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5275-3 |
Similar Items
-
Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review
by: Gatske M. Nieuwenhuyzen-de Boer, et al.
Published: (2019-07-01) -
Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients
by: Gatske M. Nieuwenhuyzen-de Boer, et al.
Published: (2023-08-01) -
The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series
by: Gatske M. Nieuwenhuyzen-de Boer, et al.
Published: (2022-12-01) -
Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study
by: Gatske M. Nieuwenhuyzen-de Boer, et al.
Published: (2022-12-01) -
Preoperative Cancer Antigen 125 Level as Predictor for Complete Cytoreduction in Ovarian Cancer: A Prospective Cohort Study and Systematic Review
by: Puck E. Brons, et al.
Published: (2022-11-01)